Branded

CRANBURY, N.J. British drug maker GlaxoSmithKline will work with U.S.-based Amicus Therapeutics to develop a drug for a rare genetic disease.

The two companies announced a deal to develop and commercialize Amigal (migalastat hydrochloride), a treatment for Fabry disease. Under the deal, GSK will pay Amicus $30 million upfront, as well as milestone payments of up to $170 million and royalties on future sales.

MOUNTAIN VIEW, Calif. Vivus found itself foiled in its efforts to market a drug for obesity as the Food and Drug Administration turned down its regulatory approval application.

BURLINGTON, Mass. Many Type 2 diabetes patients who use the drug Onglyza (saxagliptin) switched to that drug from Merck’s Januvia (sitagliptin) and Janumet (sitagliptin and metformin), according to a new report by market research firm Decision Resources.

NEW YORK Risks of counterfeiting, contamination and intellectual property theft could increase with the globalization of the pharmaceutical supply chain, according to a new report.

BALTIMORE Drug maker Pharmaxis got promising results from an investigative treatment for cystic fibrosis, the company said.

Pharmaxis announced results of two six-month phase-3 trials of 643 patients receiving Bronchitol (mannitol), which the company presented last week at the North American Cystic Fibrosis Conference in Baltimore.

LONDON British drug maker GlaxoSmithKline will pay nearly $1 billion to the U.S. government to settle allegations that it sold contaminated and ineffective products.

The company will plead guilty to criminal charges relating to drugs made at a manufacturing plant in Cidra, Puerto Rico, which it closed in 2009, and pay $750 million. In a whistleblower suit filed by a former employee, it was alleged that the company knowingly sold defective supplies of various drugs, including the baby ointment Bactroban (mupirocin) and the antidepressant Paxil (paroxetine).

NEW YORK Drug maker Keryx Biopharmaceuticals has finished enrolling participants for a late-stage clinical trial of a drug for patients on kidney dialysis, Keryx said Tuesday.

The company is conducting a phase-3 trial of Zerenex (ferric citrate) in patients with end-stage kidney disease on dialysis who have excessive phosphorous levels, a condition known as hyperphosphatemia.

Keryx said it expects to complete the study and report top-line data by the end of the year.

WOODCLIFF LAKE, N.J. Strativa Pharmaceuticals is working with a Swedish drug maker to develop and commercialize a prescription vitamin supplement, Strativa said Tuesday.

The company said it had signed a license and supply agreement with Swedish Orphan Biovitrum, also known as Sobi, concerning European rights to Strativa’s Nascobal (cyanocobalamin), a vitamin B12 nasal spray.